WHO ICTRP trial
Histological and clinical effects of Imipramine in the treatment of patients…
EUCTR2021-001328-17-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2021-001328-17-ES |
|---|---|
| Public title | Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. |
| Scientific title | Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. - HITCLIF |
| Primary sponsor | Fundación para la formación e investigación sanitarias de la Región de Murcia |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Spain |
| Conditions | Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue.;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Imipramine Product Name: Imipramine Pharmaceutical Form: Capsule, hard INN or Proposed INN: IMIPRAMINE CAS Number: 50-49-7 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use |
| Registration date | Sep 16, 2021 |
| Target size | 180 |
| Secondary IDs | IMIB-HTF-2021-01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: